Skip to main content
SpringerLink
Log in

Building a Prostate Cancer Lifestyle Medicine Program

  • Chapter
  • First Online:
Creating a Lifestyle Medicine Center

  • 594 Accesses

Abstract

According to the National Cancer Institute, there are approximately 1.7 million men living in the United States with a diagnosis of prostate cancer. To this number, approximately 230,000 new cases of prostate cancer will be diagnosed, and 29,900 men will die of the disease this year in the United States alone. Presently, there is a tremendous, unmet medical need for treating the disease, particularly early-stage prostate cancer, and as its etiology is understood in more detail, lifestyle changes are becoming an increasingly crucial part of the preventative and management process. Ethnic disparities in prostate cancer incidence and prognosis are an emerging challenge, and new immunotherapies are coming to the forefront of treatment planning in neoadjuvant, adjuvant, and advanced disease settings. Underpinning this is the knowledge that a more holistic approach to treatment has genuine benefits in terms of clinical outcomes and avoidance of treatment-related complications. With that in mind, a Lifestyle Program has been built at Mount Sinai Urology, and its development from inception through content, infrastructure, human resources, patient care and flow, reverse engineering, and future plans are all described here in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BF:

Body fat

BMI:

Body mass index

HCP:

Healthcare professional

HRQOL:

Health-related quality of life

IIEF:

International Index of Erectile Function

IPSS:

International Prostate Symptom Score

LOS:

Length of stay

MBSR:

Mindfulness-based stress reduction

MRI:

Magnetic resonance imaging

PCa:

Prostate cancer

PCP:

Primary care physician

PSA:

Prostate-specific antigen

RARP:

Robotic-assisted radical prostatectomy

TRUS:

Targeted and systematic transrectal ultrasound

References

  1. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359. https://www.ncbi.nlm.nih.gov/pubmed/25220842.

    CAS  Google Scholar 

  2. Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866–71.

    PubMed  PubMed Central  Google Scholar 

  3. Mottet N, Bellmunt J, Briers E, et al. Members of the EAU – ESTRO – ESUR –SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Copenhagen. EAU Guidelines Office: Arnhem, The Netherlands. 2018. 978-94-92671-02-8.

    Google Scholar 

  4. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308.

    PubMed  Google Scholar 

  5. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30:143–8.

    PubMed  Google Scholar 

  6. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45:385–91.

    CAS  PubMed  Google Scholar 

  7. Amin Al Olama A, et al. Multiple novel prostate cancer susceptibility signals identified by fine mapping of known risk loci among Europeans. Hum Mol Genet. 2015;24:5589–602.

    PubMed  PubMed Central  Google Scholar 

  8. Pritchard CC, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ewing CM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Lynch HT, et al. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016;138:2579–91.

    CAS  PubMed  Google Scholar 

  11. Bell KJ, et al. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137:1749–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Blanc-Lapierre A, et al. Metabolic syndrome and prostate cancer risk in a population-based case control study in Montreal. Canada BMC Public Health. 2015;15:913.

    PubMed  Google Scholar 

  13. Esposito K, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta analysis. J Endocrinol Invest. 2013;36:132–9.

    CAS  PubMed  Google Scholar 

  14. Preston MA, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012–20.

    CAS  PubMed  Google Scholar 

  15. Vidal AC, et al. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014;23:2936–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhao J, et al. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16:845.

    PubMed  PubMed Central  Google Scholar 

  17. Islami F, et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66:1054–64.

    PubMed  PubMed Central  Google Scholar 

  18. Key TJ. Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Recent Results Cancer Res. 2014;202:39–46.

    CAS  PubMed  Google Scholar 

  19. Lippi G, et al. Fried food and prostate cancer risk: systematic review and meta-analysis. Int J Food Sci Nutr. 2015;66:587–9.

    PubMed  Google Scholar 

  20. Ju-Kun S, et al. Association between Cd exposure and risk of prostate cancer: a PRISMA compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e2708.

    Google Scholar 

  21. Abrams DI. An integrative approach to prostate cancer. J Altern Complement Med (New York, NY). 2018;24(9–10):872–80.

    Google Scholar 

  22. Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39–51.

    CAS  PubMed  Google Scholar 

  23. Chen P, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e1260.

    CAS  Google Scholar 

  24. Zhang M, et al. Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases. Andrology. 2016;4:745–56.

    Google Scholar 

  25. Schröder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46–52.

    PubMed  Google Scholar 

  26. Schroder FH, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35.

    PubMed  PubMed Central  Google Scholar 

  27. Punnen S, et al. Finding the wolf in sheep’s clothing: the 4Kscore is a novel blood test that can accurately identify the risk of aggressive prostate cancer. Rev Urol. 2015;17(1):3–13.

    PubMed  PubMed Central  Google Scholar 

  28. Au D, et al. Prehabilitation and acute postoperative physical activity in patients undergoing radical prostatectomy: a secondary analysis from an Rct. Sports Med Open. 2019;5(1):1–7.

    Google Scholar 

  29. Santa Mina D, et al. Prehabilitation for radical prostatectomy: a multicentre randomized controlled trial. Surg Oncol. 2018;27(2):289–98.

    PubMed  Google Scholar 

  30. West MA, Wischmeyer PE, Grocott MPW. Prehabilitation and nutritional support to improve perioperative outcomes. Curr Anesthesiol Rep. 2017;7(4):340–9.

    PubMed  PubMed Central  Google Scholar 

  31. Katz AE. Integrative urology and prevention of prostate cancer. Altern Complement Ther. 2013;19(2):67–70.

    Google Scholar 

  32. Moyad MA. Preventing lethal prostate cancer with diet, supplements, and rx: heart healthy continues to be prostate healthy and “first do no harm” part I. Curr Urol Rep. 2018;19(12):1–9.

    Google Scholar 

  33. Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. J Clin Med. 2019;8(2). pii: E201.

    Google Scholar 

  34. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.

    Google Scholar 

  35. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23:8152–60.

    CAS  PubMed  Google Scholar 

  36. Gann PH, Deaton RJ, Rueter EE, et al. A phase II randomized trial of lycopene-rich tomato extract among men with high-grade prostatic intraepithelial neoplasia. Nutr Cancer. 2015;67:1104–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002;42:1–9.

    PubMed  Google Scholar 

  38. Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol. 2009;7:43–51.

    PubMed  Google Scholar 

  39. Thomas R, Williams M, Sharma H, et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014;17:180–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Alumkal JJ, Slottke R, Schwartzman J, et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs. 2015;33:480–9.

    CAS  PubMed  Google Scholar 

  41. Keizman D, et al. Effect of pectasol-C modified citrus pectin (p-Mcp) treatment (Tx) on psa dynamics in non-metastatic biochemically relapsed prostate cancer (Brpc) patients (Pts): results of a prospective phase II study. J Clin Oncol. 2018;36(6_suppl):14.

    Google Scholar 

  42. Xu Y, Shao X, Yao Y, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol. 2014;140:1465–77.

    CAS  PubMed  Google Scholar 

  43. Tretli S, Hernes E, Berg JP, et al. Association between serum 25 (OH) D and death from prostate cancer. Br J Cancer. 2009;100:450–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Carlson LE, Speca M, Faris P, Patel KD. One year pre– post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun. 2007;21:1038–49.

    CAS  PubMed  Google Scholar 

  45. Victorson D, Hankin V, Burns J, et al. Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: results from a randomized controlled pilot trial. Psychooncology. 2017;26:1155–63.

    PubMed  Google Scholar 

  46. Klotz L. Active surveillance for low-risk prostate cancer. Curr Urol Rep. 2015;16(4):1–10.

    Google Scholar 

  47. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065–70.

    PubMed  Google Scholar 

  48. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105:8369–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Ornish D, Lin J, Chan JM, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013;14:1112–20.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Zach Seth Dovey & Ash K. Tewari

Authors
  1. Zach Seth Dovey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ash K. Tewari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zach Seth Dovey .

Editor information

Editors and Affiliations

  1. The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and the Division of Endocrinology, Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey I. Mechanick

  2. Departments of Medicine and Medical Education, Northwestern University, Chicago, IL, USA

    Robert F. Kushner

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dovey, Z.S., Tewari, A.K. (2020). Building a Prostate Cancer Lifestyle Medicine Program. In: Mechanick, J.I., Kushner, R.F. (eds) Creating a Lifestyle Medicine Center. Springer, Cham. https://doi.org/10.1007/978-3-030-48088-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48088-2_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48087-5

  • Online ISBN: 978-3-030-48088-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation